The tyranny of non-inferiority trials

Opportunities to decrease the toxicity and cost of approved treatment regimens with lower dose, less frequent, or shorter duration alternative regimens have been limited by the perception that alternatives must be non-inferior to approved regimens. Non-inferiority trials are large and expensive to d...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The lancet oncology Ročník 25; číslo 10; s. e520 - e525
Hlavní autori:	Tannock, Ian F, Buyse, Marc, De Backer, Mickael, Earl, Helena, Goldstein, Daniel A, Ratain, Mark J, Saltz, Leonard B, Sonke, Gabe S, Strohbehn, Garth W
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.10.2024 Elsevier Limited
Predmet:	Adjuvants Cancer therapies Chemotherapy Clinical trials Clinical Trials as Topic Cost-Benefit Analysis Drug dosages Equivalence Trials as Topic FDA approval Hematology, Oncology, and Palliative Medicine Humans Meta-analysis Neoplasms - drug therapy Patient-centered care Pharmaceutical industry Research Design Schedules Toxicity United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!